Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 5/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TYMS | P04818 | 5/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252606 | 0.89 | KDM4E (0.58) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL27389640 | 0.86 | KDM4E (0.55) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL20327604 | 0.86 | KDM4E (0.55) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL31283993 | 0.86 | TRPV1 (0.58) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL27159742 | 0.86 | KDM4E (0.55) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL24625171 | 0.86 | KDM4E (0.55) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL30816135 | 0.84 | KDM4E (0.53) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL27159709 | 0.84 | KDM4E (0.53) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL23520715 | 0.84 | KDM4E (0.56) | KDM4ENPC1USP2ALDH1A1GLA | |
| SCHEMBL29991873 | 0.81 | KDM4E (0.50) | KDM4ENPC1USP2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| WO-2009046536-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046536-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2009-04-16 | — | — | WO | disclosed |
| US-7410974-B2 | Halogenated Quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-7410974-B2 | Halogenated Quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-7410974-B2 | Halogenated Quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| EP-1660486-A4 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2006-12-13 | — | — | EP | disclosed |
| US-20060258693-A1 | Halogenated quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-1660486-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | Ulysses Pharmaceuticals Products Inc. (CA) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014585-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | HRH3, HRH1, NQO2 | KDM4E 3381/4885NPC1 484/4885USP2 598/4885 |
| US-20060258693-A1 | Halogenated quinazolinyl nitrofurans as antibacterial agents | C1S, HRH1, NQO2 | KDM4E 3941/4885NPC1 193/4885USP2 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.